Vancouver, British Columbia–(Newsfile Corp. – July 28, 2020) – Veritas Pharma Inc. (CSE: VRT) (OTC Pink: VRTHF) (FSE: 2VP) (“Veritas” or the “Company“) wishes to announces that it has entered into debt settlement agreements with directors and officers to settle debt in the amount of $94,750 by the issuance of 1,263,333 common shares at a deemed price of $0.075 per share. The shares will be subject to a four month hold period from the date of issuance.

About Veritas Pharma

Veritas has developed some intellectual property relating to various cannabis strains. It is the Company’s aim to advance the science behind medical cannabis, by developing the most effective cannabis-based treatments for specific disease conditions and to acquire income-producing assets in the cannabis industry. The Company’s mission is to commercialize its proprietary cannabis products. In addition, Veritas aims to utilize its expertise to enter into mergers and acquisitions with various cannabis industry participants in order to generate revenue by the end of 2020.

Veritas Pharma Inc. is a publicly traded company in Canada, on the Canadian Securities Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.

For more information, please visit our website:

On behalf of the Board of Directors

Peter McFadden
Interim Chief Executive Officer & CFO

Further information about the Company is available on our website at or under our profile on SEDAR at, and on the CSE website at

Investor and Public Relations Contact
Veritas Pharma Inc. Telephone: +1.416.918.6785
Email: [email protected] Website:

The Veritas Newsletter

Enter your email to receive news alerts and updates from Veritas Pharma.

You have Successfully Subscribed!